Clinical Trial Update: A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating relative bioavailability of ND0612 subcutaneous levodopa versus enteral carbidopa-levodopa has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• ND0612 (ND0612)
• carbidopa-levodopa (carbidopa-levodopa)

Snippet

Sponsor: NeuroDerm Ltd. | Conditions: Parkinson | Phase 3 | Status: WITHDRAWN